Drug repositioning: auranofin as a prospective antimicrobial agent for the treatment of severe staphylococcal infections

被引：67
作者：
Cassetta, Maria Iris [1 ]
Marzo, Tiziano [2 ]
Fallani, Stefania [1 ]
Novelli, Andrea [1 ]
Messori, Luigi [2 ]
机构：
[1] Univ Florence, Dept Hlth Sci, I-50139 Florence, Italy
[2] Univ Florence, Dept Chem, I-50019 Sesto Fiorentino, Italy
来源：
BIOMETALS | 2014年 / 27卷 / 04期
关键词：
Auranofin; Antimicrobial drugs; Gold compounds; Drug repositioning; Staphyloccocal infections; CYTOKINES; COMPLEXES;
D O I：
10.1007/s10534-014-9743-6
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Auranofin, (AF), a gold(I) complex in clinical use for the therapy of rheumatoid arthritis, is reported here to produce remarkable bactericidal effects in vitro against Staphylococcus sp. Noticeably, a similar antimicrobial action and potency are also noticed toward a few methicillin-resistant Staphylococcus aureus strains but not toward Escherichia coli. The time and concentration dependencies of the antimicrobial actions of AF have been characterized through recording time kill curves, and a concentration dependent profile highlighted. Overall, the present results point out that auranofin might be quickly and successfully repurposed for the treatment of severe bacterial infections due to resistant Staphylococci.
引用
收藏
页码：787 / 791
页数：5
相关论文
共 20 条
  • [1] Aroson JK, 2007, BR J CLIN PHARM, V64, P563
  • [2] The mechanisms of action of disease-modifying antirheumatic drugs: A review with emphasis on macrophage signal transduction and the induction of proinflammatory cytokines
    Bondeson, J
    [J]. GENERAL PHARMACOLOGY-THE VASCULAR SYSTEM, 1997, 29 (02): : 127 - 150
  • [3] Predictive methods in drug repurposing: gold mine or just a bigger haystack?
    Cavalla, David
    [J]. DRUG DISCOVERY TODAY, 2013, 18 (11-12) : 523 - 532
  • [4] New uses for old drugs
    Chong, Curtis R.
    Sullivan, David J., Jr.
    [J]. NATURE, 2007, 448 (7154) : 645 - 646
  • [5] Clinical Laboratory Standards Institute (CLSI), 2004, M100S14 CLSI NCCLS
  • [6] Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
    Craig, WA
    [J]. CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) : 1 - 10
  • [7] Auranofin inhibits overproduction of pro-inflammatory cytokines, cyclooxygenase expression and PGE2 production in macrophages
    Han, Shinha
    Kim, Kwanghee
    Kim, Hyunyul
    Kwon, Jeunghak
    Lee, Young-Hee
    Lee, Chong-Kil
    Song, Youngcheon
    Lee, Sang-Jin
    Ha, Namjoo
    Kim, Kyungjae
    [J]. ARCHIVES OF PHARMACAL RESEARCH, 2008, 31 (01) : 67 - 74
  • [8] Inhibition of Selenium Metabolism in the Oral Pathogen Treponema denticola
    Jackson-Rosario, Sarah
    Self, William T.
    [J]. JOURNAL OF BACTERIOLOGY, 2009, 191 (12) : 4035 - 4040
  • [9] Auranofin disrupts selenium metabolism in Clostridium difficile by forming a stable Au-Se adduct
    Jackson-Rosario, Sarah
    Cowart, Darin
    Myers, Andrew
    Tarrien, Rebecca
    Levine, Rodney L.
    Scott, Robert A.
    Self, William Thomas
    [J]. JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY, 2009, 14 (04): : 507 - 519
  • [10] Targeting selenium metabolism and selenoproteins: Novel avenues for drug discovery
    Jackson-Rosario, Sarah Elizabeth
    Self, William Thomas
    [J]. METALLOMICS, 2010, 2 (02) : 112 - 116
12